Herbal hepatotoxicity: Challenges and pitfalls of causality assessment methods

Rolf Teschke, Christian Frenzel, Johannes Schulze, Axel Eickhoff

Abstract
The diagnosis of herbal hepatotoxicity or herb induced liver injury (HILI) represents a particular clinical and regulatory challenge with major pitfalls for the causality evaluation. At the day HILI is suspected in a patient, physicians should start assessing the quality of the used herbal product, optimizing the clinical data for completeness, and applying the Council for International Organizations of Medical Sciences (CIOMS) scale for initial causality assessment. This scale is structured, quantitative, liver specific, and validated for hepatotoxicity cases. Its items provide individual scores, which together yield causality levels of highly probable, probable, possible, unlikely, and excluded. After completion by additional information including raw data, this scale with all items should be reported to regulatory agencies and manufacturers for further evaluation. The CIOMS scale is preferred as tool for assessing causality in hepatotoxicity cases, compared to numerous other causality assessment methods, which are inferior on various grounds. Among these disputed methods are the Maria and Victorino scale, an insufficiently qualified, shortened version of the CIOMS scale, as well as various liver un-specific methods such as the ad hoc causality approach, the Naranjo scale, the World Health Organization (WHO) method, and the Karch and Lasagna method. An expert panel is required for the Drug Induced Liver Injury Network method, the WHO method, and other approaches based on expert opinion, which provide retrospective analyses with a long delay and thereby prevent a timely assessment of the illness in question by the physician. In conclusion, HILI causality assessment is challenging and is best achieved by the liver specific CIOMS scale, avoiding pitfalls commonly observed with other approaches.

Key words: Herbal hepatotoxicity; Herb induced liver injury; Herbs; Drug hepatotoxicity; Drug induced liver injury; Causality assessment

Core tip: This review focuses on diagnostic causality assessment algorithms that have been used so far in herb induced liver injury (HILI) cases. Detailed information of the various methods with their strengths and weaknesses is provided including their challenges and pitfalls that emerged during the assessing course. For the physician caring for a patient with suspected HILI, the Council for International Organizations of Medical Sciences (CIOMS) scale is the preferred tool for assessing causality compared to numerous other causality assessment methods, which are inferior on various grounds. CIOMS based assessment should start at the day HILI is suspected to ensure completeness of clinical data.
INTRODUCTION

A total of 60 herbs, herbal drugs, and herbal dietary supplements have been reported to cause herb induced liver injury (HILI), though convincing causality assessment rarely was provided[9]. Presented as a tabular compilation, these 60 different herbal products were based on a recent analysis of 185 case reports, spontaneous reports, review articles, and comments. The consideration of possible hepatotoxicity in various reports has been discussed by the National Institutes of Health (NIH) in their recently released LiverTox database, covering a selected group of herbal and dietary supplement (HDS) products[2,3]. Among these are: Aloe vera, Black cohosh (BC), Cascara, Chaparral, Chinese and other Asian herbal medicines (Ba Jiao Lian, Chi R Yun, Ephedra, Jin Bu Huan, Sho Saiko To and Dai Saiko To, Shou Wu Pian), Comfrey, Fenugreek, Germander, Ginkgo, Ginseng, Glucosamine, Greater Celandine, Green Tea, Hoodia, Horse Chestnut, Hyssop, Kava, Margosa Oil, Milk Thistle, Noni, Pennyroyal, St John’s Wort, Saw Palmetto, Senna, Skullcap, Usnic acid, Valerian, and Yohimbine[4-6]. However, causality confirmation was surprisingly rare for individual cases of suspected herbal hepatotoxicity, which often were published as narrative and anecdotal reports without valid and transparent data collection[7-9] that require stringent efforts for causality attribution[9].

The focus of this review is on causality assessment methods for herbal hepatotoxicity with particular reference to liver specific evaluation methods. This approach gives insight into challenges and pitfalls of these methods with surprising clinical and regulatory issues. Valid causality assessment of assumed HILI cases is required for further case evaluations, otherwise speculations and fruitless discussions will emerge.

DATA BASIS FOR CAUSALITY ASSESSMENT

Herbal product essentials

Herbal product quality aspects are of primary concern, the respective evaluation should start at the day HILI is suspected. The products are destined for human use and must meet the highest possible quality based on specific standards (Table 1)[8-11]. Despite fulfillment of quality standards, batch and product variability is common[12-14]. Therefore, additional specific production quality standards have been described, for instance, as a proposal for a Kava Quality Standardization Code[8]. It details standardization of overall herbal quality and specifically addresses chemical, agricultural, manufacturing, nutritional, regulatory, and legislation standardizations. In addition, labelling and consumer leaflet of herbal drugs and herbal dietary supplements should mandatorily provide a clear definition and identification of the plant family, subfamily, species, subspecies, and variety as classical botanical description for any herb used as an ingredient of a herbal product (Table 1)[8-11].

As an example, several hundred kava varieties exist[8-11], but specific information on kava variety identification was missing in all spontaneous reports and case report publications of suspected hepatotoxicity. This leaves open which kava variety had to be incriminated[8-11,15-17]. On the other hand, the regulatory recommendation for kava drugs was to use its peeled rhizome[8-11,15-17]. In various HILI cases, it remained unclear, whether unpeeled rhizomes, peeled and unpeeled roots, and/or stem peelings were also used[8-11,15-17]. This again hampered any evaluation of the causative agent of kava hepatotoxicity[8-11,15-17]. For both the United States Food and Drug Administration and the Australian Therapeutic Goods Administration, peeled kava rhizomes were recommended for kava supplements[8,10,15].

Another point of interest focuses on solvents and solubilizers without regulatory advice[8,11,15,17], as well as on adulterants, impurities, contaminants, or misidentified herbs[8,11,15,17]. These key issues of herbal product quality are rarely addressed in publications related to herbal hepatotoxicity[8-11,17].

Clinical data requirements

Other concerns focus on incomplete clinical evaluation. Beginning at the day HILI is suspected, the physician has to gather all necessary information for an accurate diagnosis and the exclusion of alternative causes under relevant clinical aspects (Tables 1 and 2)[1-3,4,8-13,17,20-26,34-39]. Hepatotoxicity requires strict criteria, best defined by alanine aminotransferase (ALT) and/or alkaline phosphatase (ALP) values[4]. Its increases are expressed in multiples of the upper limit of their normal range as N[60-62]. For ALT, hepatotoxicity has been defined from > 2N[60-62], > 3N[60-62] or > 5N[60-62], while ALP values of > 2N are commonly considered diagnostic[60-62]. Restricting ALT increases to > 5N will eliminate false positive cases and substantiate causality at a higher level of probability[60-62]. Considering patients with ALT > 2N will include numerous cases with nonspecific increases, with higher requirements for thorough assessment and more stringent exclusion of causes unrelated to the herb(s) under discussion. Also for low threshold N values, the rate of alternative diagnoses must be higher[13,14,24-26,35-39], and missing a hepatotoxicity definition results in false high case numbers due to overdiagnosing and overreporting[17,23,26,38,39]. Special care is required for reporting of confounding variables[4,13,14,18,24,39]. For clinicians, a checklist with all clinical details is available for most alternative diagnoses (Table 2)[82].

Checklist

For a pragmatic approach to assess causality, special attention by the physician is of utmost importance. Only this physician can arrange collection and assessment of all data, thereby providing good data quality. To achieve this, a checklist with all important product and clinical items (Tables 1 and 2) and a valid causality assessment...
Teschke R et al. Herbal hepatotoxicity: Causality assessment methods

Table 1 Essential steps of herbal hepatotoxicity assessments

| Quality specifications                                                                 |
|-----------------------------------------------------------------------------------------|
| Herbal product quality                                                                   |
| Good agricultural practices                                                              |
| Good manufacturing practices                                                             |
| Definition of plant family, subfamily, species, subspecies, and variety                  |
| Definition of plant part                                                                  |
| Definition of solvents and solubilizers                                                  |
| Lack of impurities, adulterants, and misidentifications                                   |
| Minimum of batch and product variability                                                 |
| Lack of variety to variety variability                                                   |
| Clinical assessment quality                                                               |
| Brand name with details of ingredients, plant parts, batch number, and expiration date  |
| Identification as herbal drug or herbal supplement                                       |
| Herb as an ingredient of a polyherbal product or an undetermined herbal product         |
| Manufacturer with address                                                                 |
| Indication of herbal use with dates of symptoms leading to herbal treatment              |
| Daily dose with details of the application form                                           |
| Exact date of herb start and herb end                                                    |
| Accurate dates of emerging new symptoms after herb start in chronological order         |
| Timeframes of challenge, latency period, and dechallenge                                 |
| Verification or exclusion of a temporal association                                       |
| Provided temporal association is verified, evaluation of a causal relationship           |
| Gender, age, body weight, height, body mass index                                         |
| Ethnicity, profession                                                                     |
| Past medical history regarding general diseases and specifically liver diseases          |
| ALT value initially including normal range                                                |
| ALT values during dechallenge up to 180 d as well as later on                            |
| ALT values during dechallenge to exclude a second peak                                    |
| ALT normalisation with exact date and actual value                                        |
| ALP value initially including normal range                                                |
| Laboratory criteria for definition of hepatotoxicity and its pattern                     |
| Definition of risk factors such as age and alcohol                                       |
| Alcohol and drug use                                                                     |
| Statement regarding actual treatment including steroids or ursodesoxycholic acid          |
| Assessment of preexisting and coexisting liver unrelated diseases                        |
| Assessment of preexisting and coexisting liver diseases                                  |
| Consideration of the several hundreds of other possible liver diseases                   |
| Providing details to exclude alternative diagnoses                                        |
| Assessment and exclusion of hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis E virus, cytomegalovirus, Epstein-Barr virus, HSV, VZV |
| Liver and biliary tract imaging including color Doppler sonography of liver vessels      |
| Specific evaluation of alcoholic, cardiac, autoimmune, and genetic liver diseases        |
| Individual quantitative score of each alternative diagnosis                             |
| Comedicated synthetic drugs, herbal drugs, herbal and other dietary supplements         |
| Definition of and search for accidental, unintended reexposure                           |
| Assessing of unintended reexposure                                                       |
| Search for evidence of prior known hepatotoxicity of the suspected herb                  |
| Assessing of known hepatotoxicity caused by the herb                                     |
| Qualified data acquisition and documentation of complete data                            |
| Transparent presentation of all data                                                     |
| Causality assessment quality                                                             |
| Prospective assessment by the physician suspecting herb induced liver injury             |
| Structured and quantitative method                                                       |
| Liver specific causality assessment method validated for hepatotoxicity                  |
| Use of the CIOMS scale                                                                   |
| Gathering of all data required for the CIOMS scale item by item                         |
| Presentation of individual CIOMS items and of scores to regulatory agency                |
| Excluding all alternative causes and presentation to regulatory agency                   |
| Regulatory case assessment by skilled hepatologist with clinical experience              |
| Regulatory assessment with assistance of external experts                                |
| Transparent presentation of regulatory verified causality assessment results             |

Required quality specifications of herbal products refer to herbs, herbal drugs, and herbal supplements including herbal mixtures. ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase; CIOMS: Council for International Organizations of Medical Sciences; HSV: Herpes simplex virus; VZV: Varicella zoster virus.
| Items to be assessed                                                                 | Information obtained |
|-----------------------------------------------------------------------------------|----------------------|
| Brand name with batch number and expiration date                                   | □                    |
| Indication of herbal use                                                           | □                    |
| Dates of symptoms leading to herbal treatment                                      | □                    |
| Daily dose                                                                         | □                    |
| Application form of herbal product                                                 | □                    |
| Exact date of herb start                                                           | □                    |
| Exact date of herb end                                                             | □                    |
| Accurate dates of emerging new symptoms after herb start in chronological order    | □                    |
| Accurate date of initially increased liver values                                  | □                    |
| Time frame of challenge                                                            | □                    |
| Time frame of latency period                                                       | □                    |
| Time frame of dechallenge                                                          | □                    |
| Verification of temporal association                                                | □                    |
| Exclusion of temporal association                                                   | □                    |
| Gender, age, body weight, height, BMI                                               | □                    |
| Ethnicity, profession                                                              | □                    |
| Past medical history and actual assessment regarding preexisting general diseases   | □                    |
| Past medical history and actual assessment regarding preexisting liver diseases     | □                    |
| Risk factors such as age and alcohol                                              | □                    |
| Quantification of alcohol and drug use                                              | □                    |
| Comedicated synthetic drugs, herbal drugs, herbal and other dietary supplements with all details of product, daily dose, exact dates of start and end of use, indication | □                    |
| ALT value initially including exact date and normal range                           | □                    |
| ALT values during dechallenge at least on days 8 and 30, and later on, with exact dates | □                    |
| ALT values during dechallenge to exclude a second peak, with exact dates           | □                    |
| ALT normalization with exact date and actual value                                 | □                    |
| ALP value initially including exact date and normal range                           | □                    |
| ALP values during dechallenge up to 180 d, and later on, with exact dates          | □                    |
| ALP values during dechallenge to exclude a second peak, with exact dates           | □                    |
| ALP normalization with exact date and actual value                                 | □                    |
| AST value initially including normal range                                         | □                    |
| Laboratory criteria for definition of hepatotoxicity                                | □                    |
| Laboratory criteria for injury pattern                                             | □                    |
| Liver and biliary tract imaging including hepatobiliary sonography, CT, MRT, MRC   | □                    |
| Color Doppler sonography of liver vessels                                          | □                    |
| Unintended reexposure                                                             | □                    |
| Known hepatotoxicity caused by the herb                                            | □                    |
| Consideration and exclusion of other possible causes                                | □                    |
| Hepatitis A                                                                        | □                    |
| Anti-HAV-IgM                                                                       | □                    |
| Hepatitis B                                                                        | □                    |
| HBsAg, anti-HBc-IgM, HBV-DNA                                                       | □                    |
| Hepatitis C                                                                        | □                    |
| Anti-HCV, HCV-RNA                                                                  | □                    |
| Hepatitis E                                                                        | □                    |
| Anti-HEV-IgM, anti-HEV-IgG, HEV-RNA                                                | □                    |
| CMV                                                                               | □                    |
| CMV-PCR, titer change for anti-CMV-IgM and anti-CMV-IgG                            | □                    |
| EBV                                                                               | □                    |
| EBV-PCR, titer change for anti-EBV-IgM and anti-EBV-IgG                            | □                    |
| HSV                                                                               | □                    |
| HSV-PCR, titer change for anti-HSV-IgM and anti-HSV-IgG                            | □                    |
| VZV                                                                               | □                    |
| VZV-PCR, titer change for anti-VZV-IgM and anti-VZV-IgG                            | □                    |
| Other virus infections                                                             | □                    |
| Specific serology of Adenovirus, Coxackie-B-virus, Echovirus, Measles virus, Rubella virus, Flavivirus, Arenavirus, Filovirus, Parvovirus, HIV, and others | □                    |
| Other infectious diseases                                                           | □                    |
| Specific assessment of bacteria, fungi, parasites, worms, and others                | □                    |
| AIH type I                                                                        | □                    |
| Gamma globulins, ANA, SMA, AAA, SLA/LP, anti-LSP, anti-ASGPR                      | □                    |
| AIH type II                                                                       | □                    |
| Gamma globulins, anti-LKM-1 (CYP 2D6), anti-LKM-2 (CYP 2C9), anti-LKM-3           | □                    |
| PBC                                                                               | □                    |
| AMA, anti-PDH-E2                                                                 | □                    |
algorithm (Tables 3-6) should be applied early in the unfolding disease, beginning at the day HILI is suspected. Unless this is done in a stringent way, poor data quality will be provided to the scientific community, regulatory agencies, expert panels, and manufacturers, disabling reevaluation of the case. Initially poor data will produce poor results and is unacceptable. Complete and excellent case data including raw data provided by the physician must be obtained for each listed item, detailed results obtained for the individual patient are to be supplemented within the checklist. BMI: Body mass index; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase; CT: Computer tomography; MRT: Magnetic resonance tomography; MRC: Magnetic resonance cholangiography; HAV: Hepatitis A virus; IgM: Immunoglobulin M; HBsAg: Hepatitis B antigen; HBc: Hepatitis B core; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HEV: Hepatitis E virus; IgG: Immunoglobulin G; HIV: Human immunodeficiency virus; CMV: Cytomegalovirus; PCR: Polymerase chain reaction; EBV: Epstein Barr virus; HSV: Herpes simplex virus; ZV: Varicella zoster virus; AIH: Autoimmune hepatitis; ANA: Anti-nuclear antibodies; SMA: Smooth muscle antibodies; AAA: Anti-actin antibodies; SLA: Soluble liver antigen; LP: Liver-pancreas antigen; LSP: Liver specific protein; ASGPR: Asialo-glycoprotein-receptor; LKM: Liver kidney microsomes; CYP: Cytochrome P450; PBC: Primary biliary cirrhosis; AMA: Anti-mitochondrial antibodies; PDH: Pyruvate dehydrogenase; PSC: Primary sclerosing cholangitis; p-ANCA: Perinuclear antineutrophil cytoplasmatic antibodies; AIC: Autoimmune cholangitis; NASH: Non alcoholic steatohepatitis; ALD: Alcoholic liver disease; DILI: Drug induced liver injury; CIOMS: Council for International Organizations of Medical Sciences; TSH: Thyroid stimulating hormone.

| PSC | □ | □ | □ |
| p-ANCA, MRC | □ | □ | □ |
| AIC | □ | □ | □ |
| ANA, SMA | □ | □ | □ |
| Overlap syndromes | □ | □ | □ |
| See AIH, PBC, PSC, and AIC | □ | □ | □ |
| NASH | □ | □ | □ |
| BMI, insulin resistance, hepatomegaly, echogenicity of the liver | □ | □ | □ |
| ALD | □ | □ | □ |
| Patient’s history, clinical and laboratory assessment, sonography | □ | □ | □ |
| DILI | □ | □ | □ |
| Patient’s history, clinical and laboratory assessment, sonography, use of the CIOMS scale | □ | □ | □ |
| Cocaine, ecstasy and other amphetamines | □ | □ | □ |
| Toxic screening | □ | □ | □ |
| Rare intoxications | □ | □ | □ |
| Toxic screening for household and occupational toxins | □ | □ | □ |
| Hereditary hemochromatosis | □ | □ | □ |
| Serum ferritin, total iron-binding capacity, genotyping for C2824 and H63D mutation, hepatic iron content | □ | □ | □ |
| Wilson’s disease | □ | □ | □ |
| Copper excretion (24 h urine), ceruloplasmin in serum, free copper in serum, Coombs-negative hemolytic anemia, hepatic copper content, Kayser-Fleisher-Ring, neurologic-psychiatric work-up, genotyping | □ | □ | □ |
| Porphyria | □ | □ | □ |
| Porphobilinogen in urine, total porphyrines in urine | □ | □ | □ |
| α1-Antitrypsin deficiency | □ | □ | □ |
| α1-Antitrypsin in serum | □ | □ | □ |
| Biliary diseases | □ | □ | □ |
| Clinical and laboratory assessment, hepatobiliary sonography, endosonography, CT, MRT, MRC | □ | □ | □ |
| Pancreatic diseases | □ | □ | □ |
| Clinical and laboratory assessment, sonography, CT, MRT | □ | □ | □ |
| Celiac disease | □ | □ | □ |
| TTG antibodies, endomysium antibodies, duodenal biopsy | □ | □ | □ |
| Anorexia nervosa | □ | □ | □ |
| Clinical context | □ | □ | □ |
| Parenteral nutrition | □ | □ | □ |
| Clinical context | □ | □ | □ |
| Cardiopulmonary diseases with shock liver (cardiac hepatopathy, ischemic hepatitis) | □ | □ | □ |
| Cardiopulmonary assessment of congestive heart disease, myocardial infarction, cardiomyopathy, cardiac valvular dysfunction, pulmonary embolism, pericardial diseases, arrhythmia, hemorrhagic shock, and various other conditions | □ | □ | □ |
| Addison’s disease | □ | □ | □ |
| Plasma cortisol | □ | □ | □ |
| Thyroid diseases | □ | □ | □ |
| TSH basal, T4, T3 | □ | □ | □ |
| Grand mal seizures | □ | □ | □ |
| Clinical context of epileptic seizure (duration > 30 min) | □ | □ | □ |
| Heat stroke | □ | □ | □ |
| Shock, hyperthermia | □ | □ | □ |
| Polytrauma | □ | □ | □ |
| Shock, liver injury | □ | □ | □ |
| Systemic diseases | □ | □ | □ |
| Specific assessment of M. Boeck, amyloidosis, lymphoma, other malignant tumors, sepsis and others | □ | □ | □ |
| Other diseases | □ | □ | □ |
| Clinical context | □ | □ | □ |
iters lacking specific scores were not considered, with the exception of the last six features. The data of the Drug Induced Liver Injury Network method are derived from the report of Rockey et al\[13\,14\,25\,35-39\,58\]. References for the other methods are found in the text. Latency period indicates time from herb start to symptoms, alternatively to abnormal liver tests. The symbol + shows that this item is present and the symbol 0 indicates lack of this item. ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; HAV: Hepatitis A virus; HBV: Hepatitis B virus; HCV: Hepatitis C virus; CMV: Cytomegalovirus; EBV: Epstein Barr virus; HSV: Herpes simplex virus; VZV: Varicella zoster virus; CIOMS: Council for International Organizations of Medical Sciences scale; MV: Maria and Victorino scale; KL method: Karch and Lasagna method; DILIN method: Drug Induced Liver Injury Network method; WHO method: World Health Organization method.

Table 3  Methods of causality assessments for suspected herbal hepatotoxicity

| Methods of causality assessment | Specific criteria of various causality assessment methods |
|--------------------------------|--------------------------------------------------------|
|                                | Expert based | Structured | Qualitative | Quantitative | Liver specific | Liver validated |
| Prospective evaluation          |              |            |             |             |                |                |
| CIOMS scale                     | No           | Yes        | No          | Yes         | Yes            | Yes            |
| MV scale                        | No           | Yes        | No          | Yes         | Yes            | Yes            |
| Naranjo scale                   | No           | Yes        | No          | Yes         | No             | No             |
| KL method                       | No           | Yes        | Yes         | No          | No             | No             |
| Ad hoc approach                 | No           | No         | No          | No          | No             | No             |
| Retrospective evaluation        |              |            |             |             |                |                |
| DILIN method                    | Yes          | Yes        | Yes         | No          | Yes            | No             |
| WHO method                      | Yes          | Yes        | No          | No          | No             | No             |
| Expert opinion                  | Yes          | No         | No          | No          | Yes            | No             |

Compilation of details are derived from previous reports\[2,3,4,5,6,7,9,11\]. Council for International Organizations of Medical Sciences scale (CIOMS scale) refers to both the original scale\[13\] and its update (Tables 5 and 6)\[62\]. Liver-specific and liver-validated criteria reflect hepatotoxicity criteria. Expert based criterion refers to the requirement of several experts for the actual case under consideration. MV scale: Maria and Victorino scale; KL method: Karch and Lasagna method; DILIN method: Drug Induced Liver Injury Network method; WHO method: World Health Organization method.

Table 4  Details of the various causality assessment methods for herb induced liver injury

| Assessed items with specific scores | CIOMS | MV | Naranjo | KL | Ad hoc | DILIN | WHO | Expert opinion |
|-----------------------------------|-------|----|---------|----|--------|-------|-----|----------------|
| Time frame of latency period      | +     | +  | 0       | 0  | 0      | 0     | 0   | 0              |
| Time frame of challenge           | +     | +  | 0       | 0  | 0      | 0     | 0   | 0              |
| Time frame of dechallenge         | +     | +  | 0       | 0  | 0      | 0     | 0   | 0              |
| Recurrent ALT or ALP increase     | +     | 0  | 0       | 0  | 0      | 0     | 0   | 0              |
| Definition of risk factors        | +     | 0  | 0       | 0  | 0      | 0     | 0   | 0              |
| Verified alternative diagnoses    | +     | +  | 0       | 0  | 0      | 0     | 0   | 0              |
| Assessed HAV, HBV, HCV           | +     | +  | 0       | 0  | 0      | 0     | 0   | 0              |
| Assessed CMV, EVB, HSV, VZV (score)| +    | +  | 0       | 0  | 0      | 0     | 0   | 0              |
| Liver and biliary tract imaging   | +     | 0  | 0       | 0  | 0      | 0     | 0   | 0              |
| Liver vessel Doppler sonography   | +     | 0  | 0       | 0  | 0      | 0     | 0   | 0              |
| Assessed preexisting diseases     | +     | 0  | 0       | 0  | 0      | 0     | 0   | 0              |
| Evaluated cardiac hepatopathy     | +     | 0  | 0       | 0  | 0      | 0     | 0   | 0              |
| Excluded alternative diagnoses    | +     | +  | 0       | 0  | 0      | 0     | 0   | 0              |
| Comedication                     | +     | 0  | 0       | 0  | 0      | 0     | 0   | 0              |
| Prior known herbal hepatotoxicity | +     | +  | 0       | 0  | 0      | 0     | 0   | 0              |
| Searched unintended exposure      | +     | +  | 0       | 0  | 0      | 0     | 0   | 0              |
| Defined unintended exposure       | +     | +  | 0       | 0  | 0      | 0     | 0   | 0              |
| Unintended exposure              | +     | +  | 0       | 0  | 0      | 0     | 0   | 0              |
| Laboratory hepatotoxicity criteria| +     | +  | 0       | 0  | 0      | +     | 0   | +              |
| Laboratory hepatotoxicity pattern | +     | +  | 0       | 0  | 0      | +     | 0   | +              |
| Liver specific method             | +     | +  | 0       | 0  | 0      | +     | 0   | +              |
| Structured, liver related method  | +     | +  | 0       | 0  | 0      | +     | 0   | +              |
| Quantitative, liver related method| +     | +  | 0       | 0  | 0      | 0     | 0   | 0              |
| Validated method for hepatotoxicity| +   | +  | 0       | 0  | 0      | 0     | 0   | 0              |

At each step of the evaluation, full transparency of all data is mandatory. This includes a complete narrative medical history, a causality assessment based on an established algorithm, and presentation of all data as item by item and raw data, ready for reevaluation by other scientists. This is also relevant for case publications and case series analyses, which is indeed feasible as shown in the past\[13\,14\,25\,35-39\,58\]. The same transparency is needed for statements and publications by regulatory agencies and expert panels. Neglecting full transparency will cause concern and uncertainty about the validity of the presented conclusions.

GENERAL ASPECTS OF CAUSALITY EVALUATION

Method categories

Some reservations exist about the best method for causality assessment. It is necessary to circumvent later investigative efforts, subsequent discussions, and speculative conclusions.
| Items for hepatocellular injury | Possible score | Patient’s score |
|--------------------------------|----------------|-----------------|
| Time to onset from the beginning of the herb |                |                 |
| 5-90 d (rechallenge: 1-15 d) | +2             |                 |
| < 5 or > 90 d (rechallenge: > 15 d) | +1             |                 |
| Alternative: Time to onset from cessation of the herb |                |                 |
| ≤ 15 d (except for slowly metabolized herbal chemicals: > 15 d) | +1             |                 |
| Course of ALT after cessation of the herb |                |                 |
| Percentage difference between ALT peak and N |                |                 |
| Decrease ≥ 50% within 8 d | +3             |                 |
| Decrease ≥ 50% within 30 d | +2             |                 |
| No information or continued herbal use | 0              |                 |
| Decrease ≥ 50% after the 30th day | 0              |                 |
| Decrease < 50% after the 30th day or recurrent increase | -2             |                 |
| Risk factors |                |                 |
| Alcohol use (drinks/d: > 2 for women, > 3 for men) | +1             |                 |
| No alcohol use (drinks/d: ≤ 2 for women, ≤ 3 for men) | 0              |                 |
| Age ≥ 55 yr | +1             |                 |
| Age < 55 yr | 0              |                 |
| Concomitant herbs(s) and drug(s) |                |                 |
| None or no information | 0              |                 |
| Concomitant herb or drug with incompatible time to onset | 0              |                 |
| Concomitant herb or drug with compatible or suggestive time to onset | -1             |                 |
| Concomitant herb or drug known as hepatotoxin and with compatible or suggestive time to onset | -2             |                 |
| Concomitant herb or drug with evidence for its role in this case (positive rechallenge or validated test) | -3             |                 |
| Search for non drug causes |                |                 |
| Group I (6 causes) |                |                 |
| Anti-HAV-IgM |                |                 |
| HBsAg, anti-HBc-IgM, HBV-DNA |                |                 |
| Anti-HCV, HCV-RNA |                |                 |
| Hepatobiliary sonography/colour Doppler sonography of liver vessels/endosonography/CT/MRC |                |                 |
| Alcoholism (AST/ALT ≥ 2 IU/L) |                |                 |
| Acute recent hypotension history (particularly if underlying heart disease) |                |                 |
| Group II (6 causes) |                |                 |
| Complications of underlying disease(s) |                |                 |
| Infection suggested by PCR and titre change for |                |                 |
| CMV (anti-CMV-IgM, anti-CMV-IgG) |                |                 |
| EBV (anti-EBV-IgM, anti-EBV-IgG) |                |                 |
| HEV (anti-HEV-IgM, anti-HEV-IgG) |                |                 |
| HSV (anti-HSV-IgM, anti-HSV-IgG) |                |                 |
| VZV (anti-VZV-IgM, anti-VZV-IgG) |                |                 |
| Evaluation of group I and II |                |                 |
| All causes-groups 1 and II - reasonably ruled out | +2             |                 |
| The 6 causes of group 1 ruled out | +1             |                 |
| 5 or 4 causes of group 1 ruled out | 0              |                 |
| Less than 4 causes of group I ruled out | -2             |                 |
| Non herb cause highly probable | -3             |                 |
| Previous information on hepatotoxicity of the herb |                |                 |
| Reaction labelled in the product characteristics | +2             |                 |
| Reaction published but unlabelled | +1             |                 |
| Reaction unknown | 0              |                 |
| Response to readministration |                |                 |
| Doubling of ALT with the herb alone, provided ALT below 5N before reexposure | +3             |                 |
| Doubling of ALT with the herb(s) and drug(s) already given at the time of first reaction | +1             |                 |
| Increase of ALT but less than N in the same conditions as for the first administration | -2             |                 |
| Other situations | 0              |                 |

The compilation of the individual items is adapted from the updated version of the Council for International Organizations of Medical Sciences (CIOMS) scale, and the original CIOMS scale. The above items refer to the hepatocellular type of injury, whereas items for the cholestatic (± hepatocellular) type are presented in Table 6. Regarding risk factor of alcohol use, 1 drink commonly contains about 10 g ethanol. Total score and resulting causality grading: ≤ 0, excluded; 1-2, unlikely; 3-5, possible; 6-8, probable; ≥ 9, highly probable. HAV: Hepatitis A virus; IgM: Immunoglobulin M; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CMV: Cytomegalovirus; CT: Computer tomography; EBV: Epstein Barr virus; Hbc: Hepatitis B core; HbsAg; Hepatitis B antigen; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HEV: Hepatitis E; HILI: Herb induced liver injury; HSV: Herpes simplex virus; MRC: Magnetic resonance cholangiography; N: Upper limit of the normal range; VZV: Varicella zoster virus.
Table 6  Updated Council for International Organizations of Medical Sciences scale for the cholestatic (± hepatocellular) type of injury with items required for causality assessment in herb induced liver injury cases

| Items for cholestatic (± hepatocellular) injury | Possible score | Patient’s score |
|-----------------------------------------------|----------------|-----------------|
| Time to onset from the beginning of the herb |               |                |
| ≤ 5-90 d (rechallenge: 1-90 d)                | +2             |                |
| < 5 or > 90 d (rechallenge: > 90 d)          | +1             |                |
| Alternative: Time to onset from cessation of the herb ≤ 30 d (except for slowly metabolized herbal chemicals: > 30 d) | +1 |                |
| Course of ALP after cessation of the herb |               |                |
| Percentage difference between ALP peak and N Decrease > 50% within 180 d | +2 |                |
| Decrease < 50% within 180 d | +1 |                |
| No information, persistence, increase, or continued herbal use | 0 |                |
| Risk factors |               |                |
| Alcohol use (drinks/d: > 2 for women, > 3 for men and pregnancy) | +1 |                |
| Alcohol use (drinks/d: ≤ 2 for women, ≤ 3 for men) | 0 |                |
| Age ≥ 55 yr | +1 |                |
| Age < 55 yr | 0 |                |
| Concomitant herbs(s) and drug(s) |               |                |
| None or no information | 0 |                |
| Concomitant herb or drug with incompatible time to onset | 0 |                |
| Concomitant herb or drug with compatible or suggestive time to onset | -1 |                |
| Concomitant herb or drug known as hepatotoxic and with compatible or suggestive time to onset | -2 |                |
| Concomitant herb or drug with evidence for its role in this case (positive rechallenge or validated test) | -3 |                |

Search for non drug causes

Group I (6 causes)
- Anti-HAV-IgM
- HBsAg, anti-HBc-IgM, HBV-DNA
- Anti-HCV, HCV-RNA
- Hepatobiliary sonography/colour Doppler sonography of liver vessels/endosonography/CT/MRC
- Alcoholism (AST/ALT ≥ 2 IU/L)
- Acute recent hypotension history (particularly if underlying heart disease)

Group II (6 causes)
- Complications of underlying disease(s)
  - Infection suggested by PCR and titre change for CMV (anti-CMV-IgM, anti-CMV-IgG)
  - EBV (anti-EBV-IgM, anti-EBV-IgG)
  - HEV (anti-HEV-IgM, anti-HEV-IgG)
  - HSV (anti-HSV-IgM, anti-HSV-IgG)
  - VZV (anti-VZV-IgM, anti-VZV-IgG)
- Evaluation of group I and II
  - All causes-groups I and II - reasonably ruled out +2
  - The 6 causes of group I ruled out +1
  - 5 or 4 causes of group I ruled out 0
  - Less than 4 causes of group I ruled out -2
  - Non herb cause highly probable -3

Previous information on hepatotoxicity of the herb
- Reaction labelled in the product characteristics +2
- Reaction published but unlabelled +1
- Reaction unknown 0

Response to readministration
- Doubling of ALP with the herb alone, provided ALP below 5N before reexposure +3
- Doubling of ALP with the herb(s) and drug(s) already given at the time of first reaction +1
- Increase of ALP but less than N in the same conditions as for the first administration -2
- Other situations 0

Total score for patient

The compilation of individual items is adapted from the updated version of the Council for International Organizations of Medical Sciences (CIOMS) scale[62] and the original CIOMS scale[60]. The above items refer to the cholestatic (± hepatocellular) type of injury, whereas items for the hepatocellular type are presented in Table 5. Regarding risk factor of alcohol use, 1 drink commonly contains about 10 g ethanol[2,3,90]. Total score and resulting causality grading: ≤ 0, excluded; 1-2, unlikely; 3-5, possible; 6-8, probable; ≥ 9, highly probable. ALP: Alkaline phosphatase; N: upper limit of the normal range; HAV: Hepatitis A virus; IgM: Immunoglobulin M; HBsAg: Hepatitis B antigen; HBc: Hepatitis B core; HBV: Hepatitis B virus; HCV: Hepatitis C virus; CT: Computer tomography; MRC: Magnetic resonance cholangiography; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; PCR: Polymerase chain reaction; CMV: Cytomegalovirus; EBV: Epstein Barr virus; HEV: Hepatitis E virus; HSV: Herpes simplex virus; IgG: Immunoglobulin G; VZV: Varicella zoster virus.
caring for a patient with suspected liver injury. This setting requires a readily available and time efficient method to evaluate causation that can adapt to further clinical and causality approach necessities. Candidates are the
Council for International Organizations of Medical Sciences (CIOMS) scale, also called Roussel Uclaf Causality Assessment
Method scale \(^{60,62}\), the Maria and Victorino (MV) scale \(^{76}\), the Naranjo scale \(^{71,72}\), the Karch and Lasagna (KL) method \(^{76}\), and the \textit{ad hoc} approach \(^{79}\).

Retrospective evaluations are based on expert panel evaluating reported or published case data, sometimes going back for months or years. Examples are the Drug Induced Liver Injury Network (DILIN) method \(^{73,78}\), the World Health Organization global introspection method (WHO method) as defined by the WHO Collaborating Centre for International Drug Monitoring \(^{81}\), and the expert opinion \(^{33,79}\). Major differences exist (Table 3), especially when assessing items that require score attribution (Table 4).

**Usage frequency**
Analyzing 23 publications of initially assumed causality but not necessarily confirmed later on with HILI cases by BC, Greater Celandine, Green Tea extracts, some Herbalife products, Hydroxycut, kava, \textit{Pelargonium sidoides}, and various herbs, the CIOMS scale was applied in 252 cases (52.2%), the WHO method in 134 cases (23.4%), the Naranjo scale in 64 cases (11.2%), the \textit{ad hoc} approach in 63 cases (11.0%), the KL method in 20 cases (3.5%), and the DILIN method in 20 cases (3.0%) \(^{60,62}\). For instance, the CIOMS scale was applied for Kava \(^{63,67}\), BC \(^{23,25,34,56,58,59,53,54,55,71}\), Greater Celandine \(^{34,38}\), \textit{Pelargonium sidoides} \(^{34,38}\), and various herbs \(^{33}\), the WHO method for Kava \(^{113,136}\), and Herbalife products \(^{54}\), the \textit{ad hoc} approach for Kava \(^{12,60}\), and Greater Celandine \(^{61}\), the Naranjo scale for BC \(^{23}\), and Green Tea extracts \(^{61}\), the KL method for Herbalife products \(^{54}\), and the DILIN method for Hydroxycut \(^{79}\).

A systematic analysis of causality methods is also available for DILI cases \(^{60,62}\). In 2008, 61 DILI publications in the PubMed database over the last decade were reviewed. It revealed that in 38 publications (62.3%) no specific causality assessment method was mentioned; presumably, the evaluation was based on the \textit{ad hoc} approach. The CIOMS scale, Naranjo scale, and WHO method were used in 10, 8, and 2 publications, respectively \(^{60,62}\). Therefore, in HILI and DILI publications the CIOMS scale was the preferred specific causality assessment method if the unstructured \textit{ad hoc} approach is excluded. Physicians are well advised to use the CIOMS scale for HILI causality evaluation, to err on the side of caution.

**NIH PREFERENCE**
The NIH LiverTox specifically addressed the item of causality in hepatotoxicity cases \(^{23}\). It focuses primarily on using the CIOMS scale, which is discussed in detail. Moreover, the MV and Naranjo scales, the Bayesian, and expert opinion assessment are referred to; details of the DILIN causality assessment also are presented. Some strengths and weaknesses of these methods are compiled (Tables 3 and 4).

**PROSPECTIVE CAUSALITY ASSESSMENT METHODS**

**CIOMS scale**
The method of choice for the causality assessment of suspected HILI is the CIOMS scale in its original form \(^{60,61}\) or preferably its update (Tables 5 and 6) \(^{60,62}\), with early starting of the evaluation at the day the physician assumes this diagnosis. The CIOMS scale is intended for prospective use at the time of manifestation; it does not require expert knowledge, is structured, quantitative, liver specific, and validated for hepatotoxicity (Table 3). Its items provide individual scores, which estimate causality levels for the agent(s) under consideration as highly probable, probable, possible, unlikely, and excluded (Tables 5 and 6). The CIOMS scale takes into account all core elements of hepatotoxicity and thereby has advantages over other algorithms (Table 4) \(^{60,62}\). Compared to the regulatory used \textit{ad hoc} approach, assessment of HILI cases with the CIOMS scale leads to lower causality grades for the incriminated herb and/or for concomitant medications and to better reproducible results due to greater transparency \(^{60,61}\).

CIOMS was developed by an international expert panel and validated by cases with positive reexposure tests serving as a gold standard \(^{60,61}\). CIOMS based assessment has shown good sensitivity (86%), specificity (89%), positive predictive value (93%), and negative predictive value (78%) \(^{61}\). The scales differ slightly for the hepatocellular and the cholestatic (± hepatocellular) type of injury (Tables 5 and 6) \(^{60,62}\). Differentiation between these types is feasible by comparing the ratio of the serum activities of ALT and ALP at diagnosis of suspected herbal hepatotoxicity \(^{60,62}\). Enzyme activity is expressed as a multiple of the upper limit of the normal range (N), and the ratio (R) of ALT/ALP is calculated. Liver injury is classified as: (1) hepatocellular, if R > 2; (2) cholestatic, when there is an increase of ALP > 2N alone or when R ≤ 2; and (3) mixed cholestatic-hepatocellular, if ALT > 2N, ALP is increased, and R between 2 and 5.

Strengths and weaknesses of the CIOMS scale have been discussed extensively \(^{23,42,73,78,82,83-91}\). This scale clearly compiles liver specific criteria for challenge, challenge, risk factors, exclusion of unrelated diseases, and com- dedication, but does not use liver histology data (Tables 5 and 6) \(^{60,62}\), agreed upon as less helpful criteria in most cases \(^{92,93}\). It considers unintentional reexposure results according to criteria as established by previous expert consensus meetings \(^{92,93}\). For reexposure results of the hepatocellular type of liver injury, ALT levels are as-


sessed before reexposure (designed as baseline ALT or ALTb), and at reexposure (designed as ALTTr). The reexposure test is positive, if (1) ALTb is below 5N with N as the upper limit of the normal value, and (2) ALTTr ≥ 2ALTb.[62]

The test is negative, if only one or no criterion is fulfilled; it is uninterpretable, if ALT data are lacking for one or both times. For reexposure assessments of the cholestatic (± hepatocellular) type of liver injury, ALT has to be replaced by ALP. Criteria for positive reexposure tests are included in the updated CIOMS scale (Tables 5 and 6) and were not previously applied in cases with reported positive reexposure tests[40-57,59,90]. When these cases were submitted to retrospective analysis using the reexposure test criteria, a positive reexposure test could be confirmed in only 13/30 cases, the test was negative in 5/30 cases and uninterpretable in 12/30 cases.[91]. In 8 cases of initially assumed Hermale hepatotoxicity with a previously reported positive reexposure test result, retrospective evaluation applying the test criteria revealed that criteria for a positive reexposure were fulfilled in only 1/8 cases, whereas the reexposure test was classified as negative in another case or the data were considered as uninterpretable due to missing information to comply adequately with the criteria in the remaining six cases.[94]

The CIOMS scale was widely used for hepatotoxicity assessments in epidemiological studies, clinical trials, case reports, case series, regulatory analyses, and genotyping studies[13,14,24,25,33,36,39,38,39,56,61,64,72,79,84,86,87,90,93-98]. Proposals for refinement and strengthening of the CIOMS scale focused on the weight of individual parameters and risk factors such as alcohol and age, and other shortcomings were addressed[34,40,47,90,98]. However, there is lack of valid data to verify improvements based on reassessing and reevaluating of published approaches[37,90,98], calling for new approaches.

Assessment of suspected HILI cases may be problematic in spontaneous reports with insufficient data. Evaluating these cases requires a sophisticated approach, as undertaken by EMA for 31 EU cases of suspected HILI by BC, using the CIOMS scale[91]. This series included 11/31 unassessable cases (35%) due to poor data quality, with causality assessment feasible in 20/31 cases (65%). Among these, EMA specified likely alternative causes in 8/20 cases with diagnoses such as autoimmune hepatitis, DILI, preexisting liver disease, alcoholic hepatitis, and preexisting liver cirrhosis with Stevens Johnson syndrome[34,98]. Causality for BC was unlikely or excluded in another 6/20 cases and 5/20 cases, respectively. In 1/20 cases, causality was judged as possible by EMA[91], but upon further evaluation this particular case with insufficient data quality was attributed with an excluded causality[91]. Consequently, in this EMA study group of 31 EU cases there was little evidence of liver injury by BC based on the use of the CIOMS scale, which was most helpful in this particular analysis and provided robust results[14]. The approach of EMA to apply the CIOMS scale in hepatotoxicity cases[14] should be highly appreciated and is in line with the corresponding recommendation by the NIH for their LiverTox database to prefer the CIOMS scale over other methods.[2,3]

At present, we are far away from valid data and strict management in suspected HILI cases, which impedes description of classic HILI by the majority of herbs. Possible or likely alternative diagnoses were evident in 278/573 cases (48.5%) of suspected HILI cases; causality assessment was impeded in 165/573 patients (29.0%) due to missing case data or lack of a temporal association, resulting in diagnostic problems in 77.5% of all cases.[82]. Given these limitations, actual discussions of validity of reported HILI cases are understandable[82,90,94,98-100], and uncertainty also extends to the validity of the type of liver injury reported for some cases lacking a probable or highly probable causality. Considering these restrictions, the hepatocellular type of injury was described for Indian Ayurvedic herbs[40-57,59,91], Chaparral (Larrea tridentata)[91], Dai Saiko To[76,87], Germander[98], Green Tea extract[87,90], Greater Celandine[91], Hydroxycut[98], Jin Bu Huan (Lysopodium serratum)[91], Kava[91], the cholestatic or mixed type for Chaparral[76,91], Germander[91], Green Tea extract[98], Greater Celandine[91], Hydroxycut[98]; and the veno-occlusive disease for plants containing pyrrolizidine alkaloids such as Senecio, Heliotropium, Crotalaria, and Symphytum species.[91]

In clinical practice, the physician will start at the day HILI is suspected with the CIOMS scale to arrive at an initial estimation and to exclude the most frequent alternative causes, provided point by point in the CIOMS questionnaire (Tables 5 and 6). The practical application of the CIOMS scale was published in various case series[13,25,33,36,38,39,71,72,91]. is shown by two single cases as examples, one for a case of hepatotoxicity by Indian Ayurvedic herbs (Table 7),[91] and another one for a case of liver injury by a dietary supplement[91]. For further refinement, specific information usually is necessary to rule out rare alternative causes (Table 2). This initial approach using the CIOMS scale ensures prospectively the collection of highly qualified case data and enables a sophisticated case evaluation currently and in the future. Information of individual CIOMS items (Tables 5 and 6), the checklist for HILI diagnosis (Table 2), all raw data, and a narrative case report should be presented to regulatory agencies, the scientific community, manufacturers, and expert panels to allow refined use of the CIOMS scale and all other case data, provided causality for the incriminated herb reached a probable or highly probable level.

**MV scale**

The MV scale[76] was developed in an attempt to improve the CIOMS scale by adding other clinical elements and by simplifying and changing the relative weight of assessment parameters, in detail discussed by the NIH LiverTox[25] and others[82,91], or briefly referenced[98]. As a shortened and modified version of the CIOMS scale[91], the MV scale[76] has fewer specific criteria than the original CIOMS scale (Table 4); due to major differences in test cases, however, the equivalency to CIOMS has been debated[2,3,40,47,87,89,91].

Specifically, the MV scale evaluates dechallenge as
Table 7  Council for International Organizations of Medical Sciences scale as an example with items required for causality assessment in a patient with herb induced liver injury by four Indian Ayurvedic herbs

| Items for hepatocellular injury                                                                 | Possible score | Psoralea corylifolia | Acacia catechu | Eclipta alba | Vetivexia zizaniodis |
|------------------------------------------------------------------------------------------------|----------------|----------------------|----------------|--------------|----------------------|
| Time to onset from the beginning of the herb                                                  |                | +2                   | +1            | +1           | +1                   |
| 5-90 d (rechallenge: 1-15 d)                                                                  |                |                      |               |              |                      |
| < 5 d or > 90 d (rechallenge: > 15 d)                                                          |                |                      | +1            | +1           | +1                   |
| Alternative: Time to onset from cessation of the herb                                         |                |                      |               |              | +1                   |
| ≤ 15 d (except for slowly metabolized herbal chemicals: > 15 d)                               |                |                      |               |              |                      |
| Course of ALT after cessation of the herb                                                     |                |                      |               |              |                      |
| Percentage difference between ALT peak and N                                                  |                | +3                   | +3            | +3           | +3                   |
| Decrease ≥ 50% within 8 d                                                                     |                |                      |               |              |                      |
| Decrease ≥ 50% within 30 d                                                                    |                |                      |               |              | +2                   |
| No information or continued herbal use                                                       |                |                      |               |              | 0                    |
| Decrease ≥ 50% after the 30th day                                                             |                |                      |               |              | 0                    |
| Decrease < 50% after the 30th day or recurrent increase                                       |                |                      |               |              | -2                   |
| Risk factors                                                                                  |                |                      |               |              |                      |
| Alcohol use (drinks/d: > 2 for women, > 3 for men)                                            |                | +1                   |               |              |                      |
| No alcohol use (drinks/d: ≤ 2 for women, ≤ 3 for men)                                        |                |                      |               |              | 0                    |
| Age ≥ 55 yr                                                                                   |                | +1                   | +1            | +1           | +1                   |
| Age < 55 yr                                                                                    |                |                      |               |              | 0                    |
| Concomitant herbs(s) and drug(s)                                                              |                |                      |               |              |                      |
| None or no information                                                                        |                | 0                    | 0             | 0            | 0                    |
| Concomitant herb or drug with incompatible time to onset                                       |                |                      |               |              | 0                    |
| Concomitant herb or drug with compatible or suggestive time to onset                           |                | -1                   | -1            | -1           | -2                   |
| Concomitant herb or drug known as hepatotoxin and with compatible or suggestive time to onset |                | -2                   | -2            | -2           | -2                   |
| Concomitant herb or drug with evidence for its role in this case (positive rechallenge or validated test) |    | -3                   |    |    |    |
| Search for non herb causes                                                                    |                |                      |               |              |                      |
| Group I (6 causes)                                                                            |                |                      |               |              |                      |
| Anti-HAV-IgM                                                                                   |                | -                    | -             | -            | -                    |
| HBsAg, anti-HBc-IgM, HBV-DNA                                                                  |                | -                    | -             | -            | -                    |
| Anti-HCV, HCV-RNA                                                                              |                | -                    | -             | -            | -                    |
| Hepatobiliary sonography/colour Doppler sonography of liver vessels/endoendosonography/CT/MRC|                | -                    | -             | -            | -                    |
| Alcoholism (AST/ALT ≥ 2 IU/L)                                                                  |                | -                    | -             | -            | -                    |
| Acute recent hypotension history (particularly if underlying heart disease)                   |                | -                    | -             | -            | -                    |
| Group II (6 causes)                                                                           |                |                      |               |              |                      |
| Complications of underlying disease(s)                                                        |                | -                    | -             | -            | -                    |
| Infection suggested by PCR and titre change for CMV (anti-CMV-IgM, anti-CMV-IgG)              |                | -                    | -             | -            | -                    |
| EBV (anti-EBV-IgM, anti-EBV-IgG)                                                               |                | -                    | -             | -            | -                    |
| HEV (anti-HEV-IgM, anti-HEV-IgG)                                                               |                | -                    | -             | -            | -                    |
| HSV (anti-HSV-IgM, anti-HSV-IgG)                                                               |                | -                    | -             | -            | -                    |
| VZV (anti-VZV-IgM, anti-VZV-IgG)                                                               |                | -                    | -             | -            | -                    |
| Evaluation of group 1 and II                                                                  |                |                      |               |              |                      |
| All causes-groups 1 and II reasonably ruled out                                               | +2             | +2                   | +2            | +2           | +2                   |
| The 6 causes of group 1 ruled out                                                              | +1             |                      |               |              |                      |
| 5 or 4 causes of group 1 ruled out                                                             | 0              |                      |               |              |                      |
| Less than 4 causes of group 1 ruled out                                                        | -2             |                      |               |              |                      |
| Non herb cause highly probable                                                                | -3             |                      |               |              |                      |
| Previous information on hepatotoxicity of the herb                                            |                |                      |               |              |                      |
| Reaction labelled in the product characteristics                                               |                | +2                   |               |              |                      |
| Reaction published but unlabelled                                                             | +1             |                      |               |              |                      |
| Reaction unknown                                                                              | 0              | 0                    | 0             | 0            | 0                    |
| Response to readministration                                                                  |                |                      |               |              |                      |
| Doubling of ALT with the herb alone, provided ALT below 5N before reeposition                 |                | +3                   |               |              |                      |
| Doubling of ALT with the herb(s) and drug(s) already given at the time of first reaction     |                | +1                   |               |              |                      |
| Increase of ALT but less than N in the same conditions as for the first administration       |                | -2                   |               |              |                      |
| Other situations                                                                              |                | 0                    |               |              |                      |
| Total score for each individual herb used by the patient                                       | +7             | +5                   | +5            | +5           | +5                   |

The data of the patient with severe hepatotoxicity by four different Indian Ayurvedic herbs are derived from a published report[58], using the updated Council for International Organizations of Medical Sciences scale for the hepatocellular type of liver injury (Table 5). The symbol - signifies that this particular item has been evaluated and no abnormality was found. Regarding risk factor of alcohol use, 1 drink commonly contains about 10 g ethanol[2,3,90]. For the four herbs, the total score was either 5 (possible causality) or 7 (probable causality). ALT: Alanine aminotransferase; N: Upper limit of the normal range; HBsAg: Hepatitis B antigen; Hbc: Hepatitis B core; HAV: Hepatitis A virus; IgM: Immunoglobulin M; HBV: Hepatitis B virus; HCV: Hepatitis C virus; CT: Computer tomography; MRC: Magnetic resonance cholangiography; AST: Aspartate aminotransferase; PCR: Polymerase chain reaction; CMV: Cytomegalovirus; EBV: Epstein Barr virus; HEV: Hepatitis E virus; HSV: Herpes simplex virus; VZV: Varicella zoster virus.
the time necessary for ALT or ALP to fall below 2N, considers a shorter latency period, asks for less accurate exclusion criteria of drug-independent causes, ignores concomitant drug use, emphasizes drugs with more than 5 years marketing without published hepatotoxicity, and overestimates extrahepatic manifestations like hypersensitivity reactions\textsuperscript{[86]}. The validation used real and fictive cases and as gold standard the opinion of three external experts\textsuperscript{[76,87]} and not cases with verified results of positive reexposure tests\textsuperscript{[80]}; for initial validation of the CIOMS scale, both a panel of experts and positive reexposure tests were used\textsuperscript{[80,81]}. Compared to the CIOMS scale\textsuperscript{[84]}, the MV scale was equivalently accurate only in cases of hypersensitivity; otherwise, the CIOMS scale was superior to the MV scale\textsuperscript{[89,90]}. A comparison of the two scales for hepatotoxicity cases demonstrated low consistency between the two systems, with agreement between the scales in only 18\% of the cases; the CIOMS scale showed better discriminative power and produced assessments closer to those of specialists\textsuperscript{[87]}. These limitations restrict the general use of the MV scale in hepatotoxicity cases\textsuperscript{[82]}.

A recent HILI study confirmed poor concordance between the MV and CIOMS scales for both the herb and concomitant medication assessment. The CIOMS scale found higher causality levels for the herb and the concomitant medicaments than the MV scale; this was associated with considerably lower causality levels provided by the MV scale compared to the \textit{ad hoc} approach\textsuperscript{[84]}. The low MV scores were attributed to various parameters such as prolonged latency and dechallenge periods, the presence of several alternative herb independent causes for the observed liver disease, only partial exclusion of herb unrelated causes due to missing essential case data, and lacking consideration of extrahepatic manifestations like rash, fever, arthralgia, peripheral eosinophilia, and cytopenia. It therefore appeared that various confounders precluded a high level of causality for the herb in a setting of HILI cases assessed by the MV scale.

The MV scale may be useful in some selected hepatotoxicity cases. Nonetheless, little evidence is provided that this scale has advantages over the CIOMS scale and should be the preferred tool\textsuperscript{[2,3,6,23,87,95,96]}. It has been criticized by the NIH LiverTox that the elements used in the MV scale and their relative weights were based upon the authors’ expert opinion and not by prospective evaluation of a variety of possible elements and different cutoff values and weights\textsuperscript{[84]}. Additional concern was expressed that the MV scale focuses on hypersensitivity features that are comparatively infrequent in hepatotoxicity cases; it performs poorly in atypical cases, such as unusually long latency periods or residual chronic symptoms after cessation of the culprit\textsuperscript{[80]}. Another issue raised was the low numbers of experts and the low degree of validation\textsuperscript{[89]} of the MV scale\textsuperscript{[70]}. Thus, the MV scale is not commonly recommended for assumed HILI cases and certainly is no substitute for the CIOMS scale\textsuperscript{[2,3,87,96]}.

**Naranjo scale**

The NIH LiverTox summarized the arguments for and against the Naranjo scale\textsuperscript{[2,3]}. In detail, while this scale includes all general features important in assessing causality, most critical elements are not weighed in judging the likelihood of liver injury, for example specific time to onset, criteria for recovery time, and list of critical diagnoses to exclude, limiting the use of this scale for assessing hepatotoxicity. The Naranjo scale includes testing for drug levels, which is rarely helpful in idiosyncratic drug induced liver disease. Finally, the scale was designed for use in clinical trials, and points are subtracted if the reaction reappears with administration of placebo, which does not apply to the usual case of drug induced liver disease. Direct comparisons to the CIOMS scale have shown that the Naranjo scale is easier to apply, but has less sensitivity and specificity in assigning causality to cases of liver injury. These statements of the NIH LiverTox\textsuperscript{[2,3]} supported other views\textsuperscript{[87]}, confirming low sensitivity, and a lower prediction rate of the Naranjo scale in a careful comparison with the CIOMS scale for suspected hepatotoxicity cases\textsuperscript{[101]}. These studies concluded that the Naranjo scale lacks validity and reproducibility when evaluating hepatotoxicity\textsuperscript{[86,91]}; it was not recommended for hepatotoxicity assessment\textsuperscript{[87]}.

The Naranjo scale was designed to assess causality of any adverse drug reaction (ADR), independent from the affected organ\textsuperscript{[1]}. It substantially differs from other causality algorithms for hepatotoxicity (Tables 3 and 4)\textsuperscript{[2,3,24-26,70,79,87,88,101]}. This scale relates toxic drug reactions to general pharmaco logical drug actions rather than possibly to idiosyncratic reactions like rare hepatotoxicity\textsuperscript{[77]}. Its items include drug concentrations and monitoring, dose relations such as decreasing dose, placebo response, cross-reactivity, and confirmation of ADRs using unidentified objective evidence, which is relevant only for toxic reactions\textsuperscript{[77,79,88]}. The general use of the Naranjo scale in hepatotoxicity cases\textsuperscript{[23,79]} created concern.

The use of the liver unspecific Naranjo scale\textsuperscript{[77]} is unacceptable in suspected HILI cases\textsuperscript{[23,79]}, its results are heavily disputed\textsuperscript{[23,24,25,63,70,79,88]}; this pertains especially to the shortened version used by the United States Pharmacopeia (USP)\textsuperscript{[23,79]} with only 5 of the original 10 items\textsuperscript{[88]}. Lack of liver specificity associated with the Naranjo algorithm is evident by lack of a definition of liver injury as ADR; an unclear time frame and latency period; undefined time frames for dechallenge; no definition of risk factors; insufficient evaluation of alternative diagnoses; inappropriate assessment of comedication; and lacking definition of a positive rechallenge test (Table 4)\textsuperscript{[77,89]}. This scale also was considered too insensitive, allowing a possible causality even in the absence of essential data, by virtue of the patient simply having taken the suspected agent\textsuperscript{[83,70]}. Most importantly, the modified Naranjo scale as used by USP\textsuperscript{[82]} did not exclude relevant alternative causes such as idiopathic autoimmune hepatitis, alcoholic or cardiac hepatopathy, other preexisting liver...
diseases, DILI, and drug-induced rhabdomyolysis. Use of this method has raised concern about judgement validity by the USP. Considering all shortcomings along with the lack of liver specificity and validation for hepatotoxicity, the Naranjo scale should be excluded from use in hepatotoxicity cases. It certainly is no substitute for the CIOMS scale.

**KL method**

The KL method is neither liver specific nor validated for hepatotoxicity. It also lacks important items for hepatotoxicity assessment. When using this approach, the physician notes the coincidence of herbal product and chemical drug and assigns causality for some Herbalife products. Subjective judgment is needed for many steps, making this method more prone to bias. Though commonly applied by the Spanish Pharmacovigilance Centres, the KL method is not used by the Spanish Group for the Study of Drug-Induced Liver Disease, which applies the CIOMS scale as the preferred assessment tool. The KL method should not be used for assessment of hepatotoxicity cases.

**Ad hoc approach**

Numerous published HILI reports lack any causality method description and presumably are based on the ad hoc assessment with its relevant shortcomings. When using this approach, the physician notes the coincidence of herbal product and chemical drug use, and will estimate the likelihood of a hepatotoxic reaction.

After ruling out alternative causes, the ad hoc approach is often used to distinguish a probable, possible, or unlikely causality. A probable causality is usually attributed when the manifestations of liver disease, temporal association, and dechallenge response seems to fit the typical signature pattern of the product in question. A possible attribution is assigned when one feature is not typical, the product not known to cause the reaction or so rarely that it is difficult to distinguish from background, or an alternative cause is less or equally plausible. An unlikely causality is assigned when most of the features are atypical or an alternative cause is more plausible.

Though relevant items such as signature of symptoms, latency period, dechallenge, definitive exclusion of alternative causes, risk factors, alcohol use, and track record of the product are used, no universally accepted description exists for either the method or its application. Due to missing specific criteria (Tables 3 and 4), the ad hoc approach is obsolete to validly assess causality in HILI or DILI cases.

With the ad hoc assessment applied prior to the liver specific CIOMS scale, the physician inevitably will postpone an assessment by such a procedure and thereby delay the diagnosis. Since the parameters of the ad hoc approach are liver unspecific and not validated (Tables 3 and 4), this method should be replaced by better alternatives. The NIH LiverTox does not even mention the ad hoc approach as a possible causality evaluation method for hepatotoxicity cases.

**RETROSPECTIVE CAUSALITY ASSESSMENT METHODS**

**DILIN method**

According to the NIH LiverTox, the DILIN method is based on a narrative summary and a compilation of clinical findings and sequential biochemical abnormalities. These are extracted from clinical records and entered into a 65-page case report form, but a scoring system was lacking, as opposed to the CIOMS scale. The DILIN causality adjunction process is outlined in a 12 step flow diagram, using three independently assessing experts in hepatotoxicity who grade the likelihood of a causal relationship between the drug and liver injury in one of five scores: (1) Definite (>95% assurance); (2) Highly likely (75% to 95% assurance); (3) Probable (50% to 74% assurance); (4) Possible (25% to 49% assurance); (5) Unlikely (<25% assurance). The causality assessment is accepted as initially scored if the three expert reviewers completely agree; if there is disagreement, the reviewers meet to reconcile the differences and reach a final single score.

A complete summary of the definitions for each category is provided.

The DILIN method requires experts and has shortcomings (Tables 3 and 4), it is therefore not suitable for the physician who needs assessment results during the early disease. The DILIN method was used for retrospective assessments of case series where time to conclusion is not a crucial issue. In combination with the CIOMS scale, this method is the basis for future DILIN group studies of clinical, genetic, environmental, and immunological risk factors. To exclude alternative causes in retrospective analyses by the DILIN method, screening was required for previous liver disease, alcohol use, hepatitis A, B, or C infection, autoimmune antibodies, ceruloplasmin, α1-antitrypsin, ferritin, iron, and...
imaging data; specific details or appropriate scores for each item were not provided (Table 4)[103]. Other possible causes were not considered (Table 2), including specific liver infections like hepatitis E or by cytomegalovirus (CMV), Epstein Barr virus (EBV), herpes simplex virus (HSV), and varicella zoster virus (VZV).[102]. At present, questions regarding the actual DILIN method validity remain, and transparent results of all diagnostic items from each individual patient would be preferred rather than a summarizing causality grade.

Another approach of the DILIN group targets a novel Causality Assessment Tool (CAT) specifically for HDS[103]. CAT was designed to retrospectively adjudicate multiple products as a single entity using structured causality assessment and expert opinion. The elements of the CAT considered the multiplicity of products consumed, implicated drugs, alternative diagnoses, and published DILI literature on the product or an ingredient[103]. In analogy to the scoring system, the DILIN method expresses causality levels as percentage assurance[103]; CAT also grades the likelihood of a causal relationship between HDS and liver injury from definitive to unlikely[103]. In this preliminary study, CAT was applied in 16 DILI cases, which were initially evaluated by the DILIN method and in which HDS are implicated as a potential cause. Overall agreement and reliability in this study of retrospective analysis requiring an expert panel was moderate[103]; this method needs further investigation and validation[103].

WHO method
In its recent statement, the NIH LiverTox does not mention the WHO method in connection with causality assessment methods for hepatotoxicity cases but rather discusses other methods[28]. Since the WHO method[80] was not developed for hepatotoxicity cases and therefore does not consider hepatotoxicity characteristics[79,104], this omission appears warranted. The shortcomings of the unspecific features of the WHO method (Tables 3 and 4) have been a matter of major concern[104] and led to the conclusion that this scale is not appropriate for causality assessment in suspected HILI cases[79,84].

The WHO method consists of two parts, one being the WHO scale to assess causality levels, the other one the global introspection by experts[84]. Though not validated for any ADR[84], global introspection surprisingly represented a popular strategy in evaluating the likelihood of drug causality for general ADRs of all organs[87]. As early as 1986, however, global introspection by experts has been shown to be neither reproducible nor valid[107]. In detail, the assessor considers factors that might support a causal link of one or more drugs to an observed ADR, lists all factors, weighs their importance, and estimates the probability of drug causation; no specific checklist or level of strength is given[107]. It has been recognized that both the questions and the answers are ambiguous[79]. Though these shortcomings are described for general ADRs, they certainly also apply even more to hepatic ADRs.

The WHO scale has not been based on a gold standard, is not quantitative, not liver specific, and has not been validated for hepatotoxicity (Tables 3 and 4)[85]. In particular, reliability, sensitivity, specificity, positive and negative predictive values are unknown, but likely are low[79,104]. Its scope is also limited since it cannot discriminate between a positive and a negative correlation, thereby resulting in overdiagnosing and overreporting[104].

The WHO method ignores relevant data like uncertainties in daily dose, temporal association, start, duration and end of herbal use, time to onset of ADR, and course of liver values after herbal discontinuation. Insufficiently considered or ignored are comedication, preexisting liver diseases, numerous alternative explanations, and exclusions of virus infections by hepatitis A, B, C and E, CMV, EBV, HSV, and VZV[68,69]. Since only a few raw data are evaluated, case duplications and retracted cases remain undetected by the WHO method to a higher degree than by other methods[69]. Despite these flaws, the WHO method was used for causality assessment[79,84]. Reconstruction often could not confirm causality in cases of two assessed reports[84], therefore, the use of the WHO method in HILI cases has major limitations.

Causality assessment by the WHO method requires a panel of experts rarely available at a hospital or a family physician office. Consequently, analyses based on this method are retrospective; their results are available long after the patient problems of assumed HILI.

Expert opinion
Expert opinion as an assessment tool is poorly defined (Tables 3 and 4), except that a panel of specialists with clinical expertise in hepatology is available for causality assessment in HILI. For DILI, groups of skilled hepatologists exist without any doubt in most countries including Japan[108] and in expert projects like the international DILI Expert Working Group[59], the United States DILIN group[38,39,104], the Spanish Group for the Study of Drug-Induced Liver Disease[86,88,90,103], and the Spanish-Latin American network on drug induced liver injury[104]. For HILI, the Hong Kong Herb-Induced Liver Injury Network is of importance[78]. However, the qualification of assessors is sometimes crucial and may be problematic as discussed in detail[88,103,104]. Even with specialists, individual opinion often results in judgement bias.

RELEVANCE TO ACTUAL MEDICAL PRACTICE
For HILI case assessment, strategies need to be developed that are clinically useful and applicable in daily practice. These must meet the expectations of the scientific community, regulatory agencies, and manufacturers, provided the case is going to be reported. At the day when HILI is suspected and criteria of hepatotoxicity are fulfilled, the physician should explore through the internet and regulatory databases how frequently the suspected herb has been associated with hepatotoxic
adverse reactions both in the scientific literature and by regulatory notifications. Publication as an interesting case report should be encouraged, if there are few or even none hepatotoxicity reports of this particular herb. Consequently, the decision will depend on the physician’s own interest and clinical experience, resulting in three different levels of assessment intensity. These include first a wait and see approach after cessation of the herbal product, second a strategy aimed at exclusion of the most frequent differential diagnoses, or third an exclusion of even rare alternative causes.

The first approach of wait and see requires little attention and few elements and is cost effective, at least initially but not necessarily in the further course. If for some reasons the correct diagnosis was missed, it will be costly and risky for the patient, the physician, or both. Submitting such an insufficiently documented case as suspected HILI case to scientific journals, regulatory agencies or manufacturers would be difficult to reconcile, leading to overreporting due to overdiagnosing. In detail, diagnostic problems including alternative diagnoses as confounding variables were evident in 77.5% of 573 cases of initially suspected HILI, presented as spontaneous reports or as published case reports.

For the second strategy, the elements of the updated CIOMS scale are sufficient, starting with the evaluation of time to onset to verify at least a temporal association between the herbal use and the liver disease (Tables 5 and 6). For instance, if clinical assessment, hepatobiliary sonography, or serology of hepatitis A-C provides an alternative cause as the correct and final diagnosis, the costs will remain low since further diagnostic measures are not warranted. If diagnostic exclusion is unsuccessful so far, parameters of CMV, EBV, HEV, HSV, and VZV are needed (Tables 5 and 6), though in reality these elements are rarely reported in suspected HILI, as detailed for DILI.

With complete or even some missing CIOMS elements, the CIOMS scale provided causality for various herbs with levels of probable and highly probable. For the third level of evaluation, the physician will have to decide, which of the multiple other and rare differential diagnoses are worth of consideration. The checklist should be valued as a reminder of possible alternatives and as a suggestion for further approaches, depending on the clinical phenotype. Clearly, the number of criteria set for ruling out alternative causes is not required for all cases, the checklist therefore asks selectively whether the information was completely, partially or not obtained (Table 2). A sophisticated strategy is needed, however, if the case is reported to regulatory agencies and the scientific community, which are overflooded by poorly documented suspected and often misdiagnosed HILI cases. For optimum case presentation, the individual items of the updated CIOMS scale should be provided for a single case (Table 7) as well as for case series. This is feasible as shown in numerous publications for 26 cases, 22 cases, 22 cases, 21 cases, 15 cases, 13 cases, and 4-9 cases. The presentation of the CIOMS items for the single case should be combined with a detailed report of all relevant case data and a list of differential diagnoses that were excluded completely or partially, or were not considered, similar to the checklist for HILI diagnosis (Table 2). For a case series, basis data for each individual case are to be provided in a single table, focusing on details required for causality assessment; examples are presented in various publications. Presentation of excellent data will lead to valid causality results and appropriate conclusions. This is prerequisite for well founded assessments of further HILI cases, with benefit for patients, physicians, the scientific community, regulatory agencies, and manufacturers.

FUTURE PERSPECTIVES

Future considerations will have to focus on improvements of causality assessment methods to obtain prospectively valid HILI diagnoses at the time the patient experiences liver injury, corresponding efforts of retrospective causality assessments of HILI cases are promising and on the way with preliminary data. Strategies are to be developed to characterize liver injury by various herbs with all facets. At the day HILI is suspected, causality assessment should be initiated in all cases using the CIOMS scale preferentially in its updated form (Tables 5 and 6). Supported by the checklist for HILI diagnosis (Table 2), this could provide HILI cases with a probable or highly probable causality for a special herb as basis for further evaluation. Overall, this will facilitate characterization of disease entities including phenotype standardization, retrospective reanalysis by expert panels, improvement of pharmacovigilance decisions, safety strategies of manufacturers, and studies directed to assess pathogenetic aspects of HILI.

Studies are needed in the future to assess factors leading to unpredictable HILI in few patients, who experience this disease with a probable or highly probable causality level. As for DILI, future issues for HILI cases with established causality are to define genetic, environmental, and immunological determinants of HILI susceptibility. Overall, metabolomics, pharmacogenetics, proteomics, and transcriptomics are areas of potential interest in HILI, as detailed for DILI. Since HILI is commonly an unpredictable disease, experimental studies dealing with predictive cellular systems as used to identify potentially hepatotoxic synthetic drugs will be of limited if any relevance for herbs. Similarly, applying well-defined primary cultures of human hepatocytes and measuring a panel of signals directly linked to key mechanisms of liver injury to predict drugs, which can cause liver injury, will be restricted to drugs and not be applicable to herbs. Recent advances of the early pre-clinical assessment of the potential intrinsic hepatotoxicity of candidates drugs has been reviewed.
in detail, focusing on cell-based models such as cell cultures with outcome and detection methods, on profiling technologies, and emerging technologies including stem cell technologies and 3D as compared to 2D culturing techniques. However, it is unlikely that the results of these in vitro studies of intrinsic and predictable hepatotoxicity induced by synthetic drugs are transferable to a clinical setting of HILI that commonly represents the idiosyncratic and unpredictable form of liver injury by one or more herbs, each with multiple chemical constituents. More important seems the search for biomarkers in HILI patients with clearly established causality.

CONCLUSION

The rare liver injury by herbs, herbal drugs, and herbal supplements may present itself with numerous facets, providing challenging issues for causality assessment. The physician is responsible to make available all necessary data for a high quality judgement; otherwise, causality evaluation will be problematic. Timely causality assessment is mandatory when the disease is unfolding to base prospective diagnostic and therapeutic decisions. The most appropriate causality assessment method is the liver specific CIOMS scale, which should prospectively be applied by the physician. If used, other methods have pitfalls and cause ambiguous results debated on reasons of imprecision, liver unspecificity, and limitations to retrospective analyses, or they are unavailable due to requirements for expert panels.

REFERENCES

1 Teschke R, Wolff A, Frenzel C, Schulze J, Eickhoff A. Herbal hepatotoxicity: a tabular compilation of reported cases. Liver Int 2012; 32: 1543-1556 [PMID: 22082722 DOI: 10.1111/j.1478-3231.2012.02864.x]
2 National Institutes of Health (NIH): NIH launches free database of drugs associated with liver injury. [cited 2013 Feb 10]. Available from: URL: http://www.nih.gov/news/health/oct2012/niddk-12.htm
3 National Institutes of Health (NIH) and LiverTox: Drug record. Herbs and dietary supplements. [cited 2013 Feb 10]. Available from: URL: http://www.livertox.nih.gov/Herbal_s_and_Dietary_Supplements.htm
4 Teschke R, Frenzel C, Glass X, Schulze J, Eickhoff A. Herbal hepatotoxicity: a critical review. Br J Clin Pharmacol 2013; 75: 630-636 [PMID: 22831551 DOI: 10.1111/j.1365-2125.2012.04395.x]
5 WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants. Geneva: WHO, 2003. [cited 2013 Feb 10]. Available from: URL: http://whqlibdoc.who.int/publications/2003/9241946271.pdf
6 Technical Report Series, No. 937, 2006. Annex 3. Supplementary guidelines on good manufacturing practices for the manufacture of herbal medicines. [cited 2013 May 18]. Available from: URL: http://whqlibdoc.who.int/trs/who_trs_937_eng.pdf
7 WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues. [cited 2013 Feb 10]. Available from: URL: http://apps.who.int/medicinedocs/documents/s14878e/s14878e.pdf
8 Teschke R, Lebot V. Proposal for a kava quality standardization code. Food Chem Toxicol 2011; 49: 2503-2516 [PMID: 21756963 DOI: 10.1016/j.fct.2011.06.075]
9 Lebot V. The quality of kava consumed in the South Pacific. HerbalGram 2006; 71: 34-37
10 Schmidt M. Quality criteria for kava. HerbalGram 2007; 73: 45-49
11 Kava and Kava Hepatotoxicity: Requirements for Novel Experimental, Ethnobotanical and Clinical Studies Based on a Review of the Evidence. Phytother Res 2011 Mar 28 [Epub ahead of print] [PMID: 21442674 DOI: 10.1002/tr.3464]
12 BFArM. Rejection of Drug Risks, Step II: Kava-Kava (Piper methysticum)-containing, and kavain-containing drugs, including homeopathic preparations with a final concentration up to, and including D4. June 14, 2002. [cited 2013 Feb 10]. Available from: URL: http://www.spc.int/cis/documents/02_0714_BFArM_Kava_Removal.pdf
13 Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008; 20: 1182-1193 [PMID: 18989142 DOI: 10.1097/MEG.0b013e3283037648]
14 Teschke R, Kava hepatotoxicity: a critical review. Ann Hepatol 2010; 9: 251-265 [PMID: 20720265]
15 Teschke R, Sarris J, Lebot V. Kava hepatotoxicity solution: A six-point plan for new kava standardization. Phytomedicine 2011; 18: 96-103 [PMID: 21112196 DOI: 10.1016/j.phymed.2010.10.002]
16 Teschke R. Kava hepatotoxicity: pathogenic aspects and prospective considerations. Liver Int 2010; 30: 1270-1279 [PMID: 20630022 DOI: 10.1111/j.1478-3231.2010.02080.x]
17 Assessments of the risk of hepatotoxicity with kava products. Geneva, Switzerland: WHO Document Production Services, 2007
18 Teschke R, Schulze J. Risk of kava hepatotoxicity and the FDA consumer advisory. JAMA 2010; 304: 2174-2175 [PMID: 20817352 DOI: 10.1001/jama.2010.1669]
19 Sarris J, Kavanagh DJ, Byrne G, Bone KM, Adams J, Deed G. The Kava Anxiety Depression Spectrum Study (KADSS), a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl) 2009; 205: 399-407 [PMID: 19430766 DOI: 10.1007/s00213-009-1549-9]
20 Estes JD, Stolzman D, Olyaei A, Corless CL, Has JM, Schwartz JM, Orloff SL. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 2003; 138: 852-858 [PMID: 12912743]
21 Seeff LB. Herbal hepatotoxicity. Clin Liver Dis 2007; 11: 577-596, vii [PMID: 17729291]
22 Navarro VJ. Herbal and dietary supplement hepatotoxicity. Semin Liver Dis 2009; 29: 373-382 [PMID: 19826971 DOI: 10.1055/s-0029-1240006]
23 Estes JD, Stolzman D, Olyaei A, Corless CL, Has JM, Schwartz JM, Orloff SL. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 2003; 138: 852-858 [PMID: 12912743]
24 Seeff LB. Herbal hepatotoxicity. Clin Liver Dis 2007; 11: 577-596, vii [PMID: 17729291]
25 Teschke R, Schmidt-Taenzer W, Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver-unspecific Naranjo scale precise enough to ascertain causality? Pharmacoeconom Drug Saf 2011; 20: 567-582 [PMID: 21702069 DOI: 10.1002/pds.2127]
26 Teschke R, Schwarzenboeck A, Schmidt-Taenzer W, Wolff A, Hennermann KH. Herb induced liver injury presumably caused by black cohosh: a survey of initially purported cases and herbal quality specifications. Ann Hepatol 2011; 10: 249-259 [PMID: 21677326]
27 Black cohosh products and liver toxicity: update. Canadian Adverse Reaction Newsletter 2010; 20: 1-3. [cited 2013 Feb 10]. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v20l6-eng.php#a11
28 Ko RJ. Adulterants in Asian patent medicines. N Engl J Med 1998; 339: 847 [PMID: 9750079]
29 Huang WF, Ken WC, Hsiao ML. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in...
Teschke R et al. Herbal hepatotoxicity: Causality assessment methods.
Bundesinstitut für Arzneimittel und Medizinprodukte bekanntmachung. Abwehr von Gefahren durch Arzneimittel, Stufe II, Anhörung: Schöllkraut-haltige Arzneimittel zur innerlichen Anwendung. [cited 2013 Feb 10]. Available from: URL: http://www.bfarm.de/cae/servlet/contentblob/1014620/publicationFile/66198/schoellkraut-anhoerung_.059505.pdf

Schulze J, Schwarzenboeck A. Suspected hepatotoxicity by Cimicifuga racemosa rhizoma (black cohosh, root): critical analysis and structured causality assessment. Phytomedicine 2009; 16: 72-84 [PMID: 19010650 DOI: 10.1016/j.phymed.2008.09.009]

Teschke R, Bahre H, Fuchs J, Wolff A. Black cohosh hepatotoxicity: quantitative causality evaluation in nine suspected cases. Menopause 2009; 16: 956-965 [PMID: 19339903 DOI: 10.1097/GME.0b013e31819d3904]

Fong TL, Kloncz KC, Canas-Coto A, Casper SJ, Durazo FA, Davern TJ, Hayashi P, Lee WM, Seef LB. Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol 2010; 105: 1561-1566 [PMID: 20104221 DOI: 10.1038/ajg.2010.5]

Manso G, López-Rivas L, Salgueiro ME, Duque JM, Jimeno FJ, Andrade RJ, Lucena MI. Continuous reporting of new cases in Spain supports the relationship between Herbalife® products and liver injury. PharmacoepidemiolDrug Saf 2011; 20: 1080-1087 [PMID: 21751292 DOI: 10.1002/ps.2180]

Nin Chau T, Cheung WI, Ngon T, Lin J, Lee KW, Tat Poon W, Leung VK, Mak T, Tse ML. Causality assessment of herb-induced liver injury using multidisciplinary approach and Roussel Uclaf Causality Assessment Method (RUCAM). Clin Toxicol (Phila) 2011; 49: 34-39 [PMID: 21114414 DOI: 10.3109/15563660.2010.537662]

Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26: 664-669 [PMID: 9303497]

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 259-245 [PMID: 7249598]

Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977; 21: 247-254 [PMID: 8375643]

Teschke R, Wolff A. Regulatory causality evaluation methods applied in kava hepatotoxicity: are they appropriate? Regul Toxicol Pharmacol 2011; 59: 1-7 [PMID: 20854865 DOI: 10.1016/j.yrtph.2010.09.006]

Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009; 32: 55-68 [PMID: 19132805 DOI: 10.2165/0000208-200902100-00005]

The use of the WHO-UISC system for standardised case causality assessment. Available from: URL: http://www.who.int/ucsm/Graphics/247874.pdf

Teschke R, Schulze J, Schwarzenboeck A, Eickhoff A, Frenzel C. Herbal hepatotoxicity: suspected cases assessed for alternative causes. Eur J Gastroenterol Hepatol 2013 Mar 18 [Epub ahead of print] [PMID: 23510966 DOI: 10.1097/MEG.0b013e328e603a89]

Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol 2008; 14: 6774-6785 [PMID: 19058303 DOI: 10.3748/wjg1.4.6774]

Teschke R, Fuchs J, Bahre H, Genthiner A, Wolff A. Kava hepatotoxicity: comparative study of two structured quantitative methods for causality assessment. J Clin Pharmacol Ther 2010; 35: 545-563 [PMID: 20836179 DOI: 10.1111/j.1365-2710.2009.01311.x]

Andrade RJ, Camargo L, Lucena MI, González-Grande R. Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf 2004; 3: 329-344 [PMID: 15268650]

Rochon J, Protiva P, Seef LB, Fontana RJ, Liangpunsakul S, Watkins PB, Davern T, McHughson JG. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008; 48: 1175-1183 [PMID: 18798540 DOI: 10.1002/hep.22442]

García-Cortés M, Stephens C, Lucena MI, Fernández-Castañer A, Andrade RJ. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol 2011; 55: 683-691 [PMID: 21349301 DOI: 10.1016/j.jhep.2011.02.007]

Teschke R, Schulze J. Suspected herbal hepatotoxicity: requirements for appropriate causality assessment by the US Pharmacopoeia. Drug Saf 2012; 35: 1091-1097 [PMID: 22897137 DOI: 10.2165/11319600-000000-00000-00000]

Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001; 33: 308-310 [PMID: 11124850]

Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, Bjornsson E, Daly AK. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806-815 [PMID: 21540079 DOI: 10.1038/cptd.2011.58]

Teschke R, Schwarzenboeck A, Eickhoff A, Frenzel C, Wolff A, Schulze J. Clinical and causality assessment in herbal hepatotoxicity. Expert Opin Drug Saf 2013; 12: 339-366 [PMID: 23458441 DOI: 10.1517/14740388.2013.774371]

Danan G. Causality assessment of drug-induced liver injury. Hepatology Working Group. J Hepatol 1986; 7: 132-136 [PMID: 3053899]

Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11: 272-276 [PMID: 2254635]

Teschke R, Schulze J, Schwarzenboeck A, Eickhoff A, Frenzel C, Wolff A. Herbal hepatotoxicity: evaluation of cases with positive reexposure tests. Submitted for publication

Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, González-Grande R, Pizarro A, Durán JA, Jiménez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmerón J, Martin-Vivaldi R. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521 [PMID: 16083708]

Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33: 123-130 [PMID: 11124828]

Avelar-Escobar G, Méndez-Navarro J, Ortiz-Olvera NX, Cas tellanos G, Ramos R, Gallardo-Cabrera VE, Vargas-Alemán Jde J, Díaz de León O, García-Muñoz B, Ramos R, Gallardo-Cabrera VE, Díaz de León O, García-Muñoz B, Ramos R, Gallardo-Cabrera VE. Hepatotoxicity associated with dietary energy supplements: use and abuse by young athletes. Ann Hepatol 2012; 11: 564-569 [PMID: 22706411]

Bunchornvatkal C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther 2013; 37: 3-17 [PMID: 23121117 DOI: 1111/apt.12109]

Appelhans K, Najeullah R, Frankos V. Letter: retrospective reviews of liver-related case reports allegedly associated with Herbalife present insufficient and inaccurate data. Aliment Pharmacol Ther 2013; 37: 753-754 [PMID: 23458553 DOI: 1111/apt.12217]

Reddy KR, Bunchornvatkal C. Letter: retrospective reviews
of liver-related case reports allegedly associated with Herb-alife present insufficient and inaccurate data--authors' reply. *Aliment Pharmacol Ther* 2013; 37: 754-755 [PMID: 23458534 DOI: 10.1111/apt.12242]

101 **García-Cortés M**, Lucona MI, Andrade RJ, Camargo R, Alcántara R. Is the Naranjo probability scale adequate enough to ascertain causality in drug-induced hepatotoxicity? *Ann Pharmacother* 2004; 38: 1540-1541 [PMID: 15266043]

102 **Rockey DC**, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, Fontana RJ, Hayashi PH. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. *Hepatology* 2010; 51: 2117-2126 [PMID: 20512999 DOI: 10.1002/hep.23577]

103 **Navarro VJ**, Barnhart HX, Bonkovsky HL, Reddy KR, Seeff L, Serrano J, Talwalkar JA, Vega M, Vuppulanchi R. Diagnosing hepatotoxicity attributable to herbal and dietary supplements: test-retest reliability of novel causality assessment tool. *J Hepatol* 2012; 55 (Suppl 2): S536

104 **Teschke R**, Eickhoff A, Wolff A, Frenzel C, Schulze J. Herbal hepatotoxicity and WHO global introspection method. *Regul Toxicol Pharmacol* 2012; 64: 343-344 [DOI: 10.1016/j.yrtph.2012.06.010]

105 **Stammeschulte T**, Gundert-Remy U. Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: Was causality adequately ascertained? *Regul Toxicol Pharmacol* 2012; 64: 342; author reply 343-344 [PMID: 22728685 DOI: 10.1016/j.yrtph.2012.06.011]

106 **Kramer MS**. Assessing causality of adverse drug reactions: Global introspection and its limitations. *Drug Inf J* 1986; 20: 433-437

107 **Takikawa H**, Takamori Y, Kumagi T, Onji M, Watanabe M, Shibuya A, Hisamochi A, Kumashiro R, Ito T, Mitsumoto Y, Nakamura A, Sakaguchi T. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. *Hepatol Res* 2003; 27: 192-195 [PMID: 14585995 DOI: 10.1016/S1386-6346(03)00252-8]

108 **Au JS**, Navarro VJ, Rossi S. Review article: Drug-induced liver injury--its pathophysiology and evolving diagnostic tools. *Aliment Pharmacol Ther* 2011; 34: 11-20 [PMID: 21539586 DOI: 10.1111/j.1365-2036.2011.04674.x]

109 **Chalasani N**, Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. *Gastroenterology* 2010; 138: 2246-2259 [PMID: 20394749 DOI: 10.1053/j.gastro.2010.04.001]

110 **Xu JJ**, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D. Cellular imaging predictions of clinical drug-induced liver injury. *Toxicol Sci* 2008; 105: 97-105 [PMID: 18524759 DOI: 10.1093/toxsci/kfn109]

111 **Larrey D**, Faure S. Herbal medicine hepatotoxicity: a new step with development of specific biomarkers. *J Hepatol* 2011; 54: 599-601 [PMID: 21167851 DOI: 10.1016/j.jhep.2010.12.003]